Damian McNamara is a journalist for Medscape Medical News and MDedge. He worked full-time for MDedge as the Miami Bureau covering a dozen medical specialties during 2001-2012, then as a freelancer for Medscape and MDedge, before being hired on staff by Medscape in 2018. Now the two companies are one. He uses what he learned in school – Damian has a BS in chemistry and an MS in science, health and environmental reporting/journalism. He works out of a home office in Miami, with a 100-pound chocolate lab known to snore under his desk during work hours.
News
Moderna filing for FDA emergency COVID-19 vaccine approval, reports 94.1% efficacy
Vaccine efficacy remained consistent across different groups analyzed by age, race/ethnicity, and gender.
News
IDSA updates COVID guidelines for antibodies, antivirals, other drugs
Panel cautions against routine use of bamlanivimab and notes that remdesivir can shorten the clinical course of COVID-19.
News
Debate: After methotrexate failure, is JAK inhibitor or biologic next?
Experts pointed to differences in safety, clinical experience, and cost when considering Janus kinase inhibitors or biologic treatment after a...
News
Pfizer’s COVID-19 vaccine 95% effective in final phase 3 results
The vaccine was well tolerated with no serious safety concerns.
Article
Moderna: Interim data show 94.5% efficacy for COVID-19 vaccine, will seek FDA EUA
The first interim results of the phase 3 COVE trial included 95 participants with confirmed COVID-19.
News
Methotrexate and hydroxychloroquine split on cardiovascular outcomes in RA
Some distinctions in risk for heart failure, myocardial infarction, and stroke emerged between agents.
News
FDA grants emergency use authorization to Lilly’s antibody COVID-19 therapy
“We have supplies to distribute now. Product distribution will begin this week.”
News
FAST trial clears febuxostat of increased mortality in gout
Researchers in Europe compare adverse cardiovascular events, including mortality, between febuxostat and allopurinol among older adults with gout...
News
Denosumab favored over alendronate for BMD protection in glucocorticoid-induced osteoporosis
Denosumab “may be considered as an alternative first-line therapy in higher-risk patients and in those who are contraindicated for the oral...
News
Higher cardiovascular risks in Kawasaki disease persist 10-plus years
Researchers evaluated the incidence of myocardial infarction, stroke, death, and more in a follow-up study of Kawasaki disease survivors, compared...
News
COVID-19 risks in rheumatic disease remain unclear
Elevated COVID-19-related risks, many associated with comorbidities, emerged in a match-control study, whereas a systematic review delivers more...
News
Common SARS-CoV-2 mutation may be making COVID-19 more contagious
In contrast to a greater variety of strains early in the pandemic, now 99.9% of circulating SARS-CoV-2 strains in the study feature the D614G...
News
About 17% of COVID-19 survivors retest positive in follow-up study
The findings could carry important implications for people who continue to be symptomatic.